Clever Leaves Holdings Inc. CLVR
We take great care to ensure that the data presented and summarized in this overview for Clever Leaves Holdings Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CLVR
View allLatest Institutional Activity in CLVR
Top Purchases
Top Sells
About CLVR
Clever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.
Insider Transactions at CLVR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 08
2024
|
Henry R Hague Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
170
-1.4%
|
$510
$3.31 P/Share
|
Feb 27
2024
|
Henry R Hague Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
411
-3.28%
|
$1,233
$3.95 P/Share
|
Jan 19
2024
|
Julian Wilches Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
131
-1.74%
|
$262
$2.88 P/Share
|
Jan 19
2024
|
Andres Fajardo Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,561
-6.68%
|
$3,122
$2.88 P/Share
|
Dec 20
2023
|
Andres Fajardo Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
177
-0.03%
|
$354
$2.04 P/Share
|
Dec 20
2023
|
Julian Wilches Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
135
-0.06%
|
$270
$2.04 P/Share
|
Jul 18
2023
|
Julian Wilches Chief Regulatory Officer |
SELL
Open market or private sale
|
Direct |
813
-0.35%
|
$0
$0.22 P/Share
|
Jul 18
2023
|
Andres Fajardo Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,938
-0.41%
|
$0
$0.22 P/Share
|
Jul 18
2023
|
Henry R Hague Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,560
-0.41%
|
$0
$0.22 P/Share
|
Jun 29
2023
|
Gary M Julien Director |
SELL
Open market or private sale
|
Direct |
251
-0.21%
|
$0
$0.21 P/Share
|
Jun 29
2023
|
William Muecke Director |
SELL
Open market or private sale
|
Direct |
251
-0.23%
|
$0
$0.21 P/Share
|
May 31
2023
|
George J Schultze Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+25.76%
|
-
|
May 31
2023
|
Elisabeth H Demarse Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.65%
|
-
|
May 31
2023
|
Gary M Julien Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.65%
|
-
|
May 31
2023
|
William Muecke Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+26.58%
|
-
|
May 31
2023
|
Henry R Hague Iii Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
183,000
+32.65%
|
-
|
May 31
2023
|
Andres Fajardo Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
183,000
+20.52%
|
-
|
May 31
2023
|
Julian Wilches Chief Regulatory Officer |
BUY
Grant, award, or other acquisition
|
Direct |
183,000
+44.2%
|
-
|
Mar 03
2023
|
Henry R Hague Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,678
-2.84%
|
$0
$0.37 P/Share
|
Feb 24
2023
|
Henry R Hague Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,018
-4.31%
|
$0
$0.42 P/Share
|
Last 12 Months Summary
Open market or private sale | 2.27K shares |
---|